Grifols' US arm to sell ADI's colon cancer monitor
This article was originally published in Clinica
Executive Summary
AMDL Diagnostics (ADI) has enlisted Grifols, one of Spain's largest and most established healthcare multinationals, as the exclusive distributor of its colorectal cancer test. The five-year agreement will see Grifols USA market the DR-70 Onko-Sure test to hospitals and labs nationwide, for monitoring the recurrence of colorectal cancer. ADI was created in August by its parent company, Tustin, California-based Radient Pharmaceuticals (formerly known as AMDL), to focus exclusively on the commercialisation of Onko-Sure (www.clinica.co.uk, August 21 2009). According to Radient, around 151,000 new cases of colorectal cancer were diagnosed in the US in 2008 – almost half of all patients thought to be cured are expected to develop a recurrence of the cancer within five years, usually due to undetected metastases.